The use of everolimus in renal-transplant patients

References

• Meier-KriescheHUScholdJDSrinivasTRKaplanBLack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent eraAm J Transplant2004437838314961990
   PubMed Web of Science ®Google Scholar
• ChapmanJRO’ConnellPJNankivellBJChronic renal allograft dysfunctionJ Am Soc Nephrol2005163015302616120819
   PubMed Web of Science ®Google Scholar
• NankivellBJBorrowsRJFungCLCalcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histologyTransplantation20047855756515446315
   PubMed Web of Science ®Google Scholar
• SchulerWSedraniRCottensSSDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivoTransplantation19976436429233698
   PubMed Web of Science ®Google Scholar
• LorberMIMulgaonkarSButtKMEverolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III studyTransplantation20058024425216041270
   PubMed Web of Science ®Google Scholar
• VitkoSMargreiterRWeimarWThree-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patientsAm J Transplant200552521253016162203
   PubMed Web of Science ®Google Scholar
• VitkoSTedescoHErisJEverolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studiesAm J Transplant2004462663515023156
   PubMed Web of Science ®Google Scholar
• AbrahamRTWiederrechtGJImmunopharmacology of rapamycinAnnu Rev Immunol1996144835108717522
   PubMed Web of Science ®Google Scholar
• ViklickyOZouHMullerVSDZ RAD prevents manifestation of chronic rejection in rat renal allograftsTransplantation20006949750210708101
   PubMed Web of Science ®Google Scholar
• SchuurmanHJCottensSFuchsSSDZ RAD, a new rapamycin derivative: synergism with cyclosporineTransplantation19976432359233697
   PubMed Web of Science ®Google Scholar
• CaoWMohacsiPShorthouseRPrattRMorrisREEffects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506Transplantation1995593903957532879
   PubMed Web of Science ®Google Scholar
• SchuurmanHJPallyCWeckbeckerGSchulerWBrunsCSDZ RAD inhibits cold ischemia-induced vascular remodelingTransplant Proc1999311024102510083455
   PubMed Web of Science ®Google Scholar
• LutzJZouHLiuSAntusBHeemannUApoptosis and treatment of chronic allograft nephropathy with everolimusTransplantation20037650851512923436
   PubMed Web of Science ®Google Scholar
• LorberMIPonticelliCWhelchelJTherapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety dataClin Transplant20051914515215740547
   PubMed Web of Science ®Google Scholar
• PascualJEverolimus in clinical practice – renal transplantationNephrol Dial Transplant200621Suppl 3iii18iii2316815852
   PubMed Web of Science ®Google Scholar
• BennettWMThe nephrotoxicity of immunosuppressive drugsClin Nephrol199543Suppl 1S3S77540121
   PubMed Web of Science ®Google Scholar
• NashanBCurtisJPonticelliCEverolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label studyTransplantation2004781332134015548972
   PubMed Web of Science ®Google Scholar
• ChanLGreensteinSHardyMAMulticenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectivenessTransplantation20088582182618360262
   PubMed Web of Science ®Google Scholar
• PascualJConcentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitorsTransplantation200579S76S7915880020
   PubMed Web of Science ®Google Scholar
• KovarikJMTedescoHPascualJEverolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantationTher Drug Monit20042649950515385832
   PubMed Web of Science ®Google Scholar
• EVEREST.ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/show/NCT00170885?term=CRAD001AIT02&rank=1. Accessed 05 January 2009.
   Google Scholar
• Study A2309.ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/show/NCT00251004?term=crad001a2309&rank=1. Accessed 05 January 2009.
   Google Scholar
• Study A2426.ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/show/NCT00369161?term=CRAD001A2426&rank=1. Accessed 05 January 2009.
   Google Scholar
• HERAKLES Study.ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT00514514?term=crad001ade13&rank=1. Accessed 05 January 2009.
   Google Scholar
• Study A2419.ClinicalTrials.gov Available from: http://www.clini-caltrials.gov/ct2/show/NCT00154284?term=crad001a2419&rank=1. Accessed 05 January 2009.
   Google Scholar
• Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients (ASCERTAIN) study (A2413).ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT00170846?term=crad001a2413&rank=1. Accessed 05 January 2009.
   Google Scholar
• HoldaasHBentdalOPfefferPEarly, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot studyClin Transplant20082236637118279419
   PubMed Web of Science ®Google Scholar
• MoriceMCSerruysPWSousaJEA randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularizationN Engl J Med20023461773178012050336
   PubMed Web of Science ®Google Scholar
• GrubeESonodaSIkenoFSix- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymerCirculation20041092168217115123533
   PubMed Web of Science ®Google Scholar
• NashanBThe role of Certican (everolimus, rad) in the many pathways of chronic rejectionTransplant Proc2001333215322011750380
   PubMed Web of Science ®Google Scholar
• FishmanJAEmeryVFreemanRCytomegalovirus in transplantation – challenging the status quoClin Transplant20072114915817425738
   PubMed Web of Science ®Google Scholar
• DemopoulosLPolinskyMSteeleGReduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trialsTransplant Proc2008401407141018589118
   PubMed Web of Science ®Google Scholar
• Gutierrez-DalmauACampistolJMThe role of proliferation signal inhibitors in post-transplant malignanciesNephrol Dial Transplant200722Suppl 1i11i1617360768
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet200837244945618653228
   PubMed Web of Science ®Google Scholar
• PascualJBoletisINCampistolJMEverolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directionsTransplant Rev200620118
   Google Scholar
• KuypersDRBenefit-risk assessment of sirolimus in renal transplantationDrug Saf20052815318115691225
   PubMed Web of Science ®Google Scholar
• StephanyBRAugustineJJKrishnamurthiVDifferences in proteinuria and graft function in de novo sirolimus-based vs calcineurin inhibitor-based immunosuppression in live donor kidney transplantationTransplantation20068236837416906035
   PubMed Web of Science ®Google Scholar
• Tedesco-SilvaHJrVitkoSPascualJ12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipientsTranspl Int200720273617181650
   PubMed Web of Science ®Google Scholar
• KeaneWFProteinuria: its clinical importance and role in progressive renal diseaseAm J Kidney. Dis200035S97S10510766008
   PubMed Web of Science ®Google Scholar
• DiekmannFBuddeKOppenheimerFPredictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunctionAm J Transplant200441869187515476488
   PubMed Web of Science ®Google Scholar
• LetavernierELegendreCmToR inhibitors-induced proteinuria: mechanisms, significance, and managementTransplant Rev (Orlando)20082212513018631865
   PubMedGoogle Scholar
• MuirheadNHouseAHollombyDJJevnikarAMEffect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathyTransplant Proc2003352412241414611973
   PubMed Web of Science ®Google Scholar
• AugustineJJBodziakKAHricikDEUse of sirolimus in solid organ transplantationDrugs20076736939117335296
   PubMed Web of Science ®Google Scholar
• AndresVCastroCCampistolJMPotential role of proliferation signal inhibitors on atherosclerosis in renal transplant patientsNephrol Dial Transplant200621Suppl 3iii14iii1716815851
   PubMed Web of Science ®Google Scholar
• MagnaniGViganoMMaccheriniMEverolimus- vs MMF-based immunosuppression: comparable lipid profiles at one year after cardiac transplantation [poster]. American Transplant Congress, Toronto, Canada, 30 May – 4 JuneAm J Transplant20088S2347
   Google Scholar
• KasiskeBLdeMAFlechnerSMMammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipientsAm J Transplant200881384139218510633
   PubMed Web of Science ®Google Scholar
• KovarikJMHartmannSHubertMPharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimusJ Clin Pharmacol20024222222811831546
   PubMed Web of Science ®Google Scholar
• EllosoMMAzrolanNSehgalSNProtective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient miceAm J Transplant2003356256912752312
   PubMed Web of Science ®Google Scholar
• PakalaRStabileEJangGJClavijoLWaksmanRRapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxisJ Cardiovasc Pharmacol20054648148616160601
   PubMed Web of Science ®Google Scholar
• WaksmanRPakalaRBurnettMSOral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out miceCardiovasc Radiat Med20034343812892771
   PubMedGoogle Scholar
• PascualJMarcenROrtunoJClinical experience with everolimus (Certican): optimizing dose and tolerabilityTransplantation200579S80S8415880021
   PubMed Web of Science ®Google Scholar
• TroppmannCPierceJLGandhiMMHigher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot studyTransplantation20037642642912883205
   PubMed Web of Science ®Google Scholar
• MargreiterRVitkoSWhelchelJPost-operative tissue regeneration in renal transplantation: comparable outcome with everolimus or MMF. Transplantation Society XXII Annual Congress, August 10–14, Sydney, AustraliaTransplantation200886S2188
   Google Scholar
• MohauptMGVogtBFreyFJSirolimus-associated eyelid edema in kidney transplant recipientsTransplantation20017216216411468553
   PubMed Web of Science ®Google Scholar
• MoroJAAlmenarLMartinez-DolzLTolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantationTransplant Proc2008403034303619010183
   PubMed Web of Science ®Google Scholar
• ChampionLSternMIsrael-BietDBrief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipientsAnn Intern Med200614450550916585664
   PubMed Web of Science ®Google Scholar
• GarreanSMassadMGTshibakaMSirolimus-associated interstitial pneumonitis in solid organ transplant recipientsClin Transplant20051969870316146565
   PubMed Web of Science ®Google Scholar
• HaydarAADentonMWestAReesJGoldsmithDJSirolimus-induced pneumonitis: three cases and a review of the literatureAm J Transplant2004413713914678046
   PubMed Web of Science ®Google Scholar
• RehmBKellerFMayerJStrackeSResolution of sirolimus-induced pneumonitis after conversion to everolimusTransplant Proc20063871171316647451
   PubMed Web of Science ®Google Scholar
• DeSPPetruccelliSPrecisiASwitch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient – not all proliferation signal inhibitors are the same: a case reportTransplant Proc2007393500350118089420
   PubMed Web of Science ®Google Scholar
• Mycophenolate sodium vs Everolimus or Cyclosporine with Allograft Nephropathy as Outcome (MECANO) studyNetherlands Trial Register Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=567. Accessed 05 January 2009.
   Google Scholar
• CALLISTO.ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/show/NCT00154297?term=CRAD001A2420&rank=2. Accessed 05 January 2009.
   Google Scholar
• ZEUS.ClinicalTrials.gov Available from:http://clinicaltrials.gov/ct2/show/NCT00154310?term=CRAD001A2418&rank=1. Accessed 05 January 2009.
   Google Scholar
• Steroid Or Cyclosporine Removal After Transplantation using EverolimuS (SOCRATES) study (A2421).ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT00371826?term=crad001a2421&rank=1. Accessed 05 January 2009.
   Google Scholar
• Study A2423.ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT00170807?term=crad001a2423&rank=1. Accessed 05 January 2009.
   Google Scholar
• KamarNJaafarAEspositoLConversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: results of a 6-month pilot studyClin Nephrol20087011812518793527
   PubMed Web of Science ®Google Scholar